Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herceptin early-stage breast cancer user fee date extended

This article was originally published in The Pink Sheet Daily

Executive Summary

New deadline is November after Genentech provides FDA with additional analyses of previously submitted studies.

You may also be interested in...



Herceptin Approved For Early-Stage Adjuvant Breast Cancer

The average cost per course of therapy in the adjuvant indication is significantly more than for metastatic cancer.

Herceptin Approved For Early-Stage Adjuvant Breast Cancer

The average cost per course of therapy in the adjuvant indication is significantly more than for metastatic cancer.

Herceptin sBLA Submitted For Early-Stage Use

A supplemental BLA for an early adjuvant breast cancer indication for Herceptin will have a mid-August user fee date, if granted priority review

Topics

UsernamePublicRestriction

Register

PS064661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel